Company Overview
KALA BIO, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the research, development, and commercialization of therapies specifically designed for rare and severe eye diseases. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself to address unmet medical needs in ophthalmology through specialized therapeutic innovation. Currently, the organization employs 38 individuals and maintains a market capitalization of $195.30M, while its annual revenue for the trailing twelve months is not available in the provided financial data. These valuation figures indicate that the market values the firm based on its clinical pipeline potential rather than current profitability, a common characteristic for early-stage biotechnology entities that are still navigating the high-cost phases of drug development. The absence of reported revenue combined with a specific market cap suggests the company is in a pre-commercialization phase where capital allocation is driven by research expenditures and clinical trial progress rather than sales generation.
Financial Health
The company reported a net income of $-35,841,000 and an EBITDA of $-41,311,000 for the trailing twelve months, with revenue figures not currently disclosed. The significant gap between the reported net income and EBITDA, both of which are negative, reveals a cost structure heavily weighted toward operational expenses and likely research and development costs that exceed any current income generation. Free cash flow stands at $-22,026,250, indicating that the company is burning cash to fund its operations and clinical trials, which limits immediate financial flexibility but is typical for development-stage enterprises. All three reported margins—Gross Margin, Operating Margin, and Profit Margin—are listed as 0.0%, which indicates that the company has not yet achieved profitability or that its accounting structure results in zero margin reporting due to the nature of its clinical-stage activities. On the balance sheet, the company holds $21.10M in cash against $29.94M in debt, resulting in a debt-to-equity ratio that is not available, suggesting a leveraged position relative to its cash reserves. The current ratio is 0.74, which indicates that the company's current liabilities exceed its current assets, pointing to potential short-term liquidity challenges that require careful management of cash burn rates. Return on Assets is -65.8%, while Return on Equity is not available, revealing that the company's assets are generating negative returns and that equity holders are experiencing value erosion at the current stage of development.
Valuation Assessment
The trailing twelve-month P/E ratio is not available, while the forward P/E is listed as -0.03, a metric that implies the market does not anticipate positive earnings in the near future and reflects the company's current unprofitable status. The price-to-book ratio is -0.18, which indicates that the market is valuing the company significantly below its book value, a situation often seen in distressed or pre-revenue biotechnology firms where intangible assets and clinical data are not fully captured on the balance sheet. The price-to-sales ratio is not available, and the EV/EBITDA stands at -0.26, suggesting that traditional multiple-based valuation methods are not applicable due to the negative earnings and lack of sales data. The stock has traded with a 52-week high of $20.60 and a 52-week low of $0.21, illustrating an extreme volatility range where the current price sits well below the recent high, reflecting the uncertainty surrounding the company's clinical outcomes. The beta value is -2.37, which is an anomalous metric for most equities but suggests that the stock's price moves with a magnitude and direction inversely correlated to the broader market or specific sector benchmarks, highlighting unique risk factors associated with this specific biotechnology asset.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue at this specific point in the company's lifecycle. As a non-dividend payer, the company reports a dividend yield of not available and a payout ratio of 0.0%, confirming that all available financial resources are being reinvested into research, development, and clinical trials rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage biopharmaceutical companies that prioritize advancing their lead product candidates, such as KPI-012, over providing immediate income to investors. The overall growth and income profile is characterized by a complete absence of current earnings growth or dividend distribution, with the company's value entirely dependent on the successful progression of its pipeline through Phase 2b clinical trials and future commercialization milestones.